Slow‐wave sleep and delta power in rapid eye movement sleep behavior disorder

Massicotte-Marquez, Jessica; Carrier, Julie; Décary, Anne; Mathieu, Annie; Vendette, Mélanie; Petit, Dominique; Montplaisir, Jacques

doi:10.1002/ana.20373

Cited by 75 publications

(52 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Considering that quantitative electroencephalographic (EEG) analysis has been regarded as a useful tool for characterizing patients in early-stage Alzheimer's disease, DLB and PD with dementia [22], many researchers have aimed to ascertain possible associations of quantitative EEG findings while both awake and asleep to cognitive findings or descriptive RBD variables [23,24,25]. Here, we introduce the progress in quantitative EEG research in iRBD during the past decade and discuss the clinical significance and mechanism of abnormal EEG findings in patients with the disorder.…”

Section: Disease Concept Prevalence and Clinical Correlates Of The Rmentioning

confidence: 99%

Electroencephalographic Finding in Idiopathic REM Sleep Behavior Disorder

2015

View full text Add to dashboard Cite

The REM sleep behavior disorder (RBD) is a type of parasomnia manifested by vivid, often frightening dreams associated with motor behaviors during REM sleep, sometimes causing injuries to patients themselves or to their bed partners. The polysomnographic features of RBD include increased muscle activity during REM sleep (REM sleep without atonia). The majority of RBD-affected persons are older men. The disorder might be idiopathic (iRBD) or secondary to neurological disorders of various kinds. iRBD management with pharmaceutical measures is usually straightforward and effective. Several longitudinal studies have revealed that a high proportion of iRBD patients convert to α-synucleinopathies such as Parkinson's disease and dementia with Lewy body disease (DLB). Considering this, many studies have been conducted to identify common clinical markers between α-synucleinopathies and iRBD or indicators for the future development of α-synucleinopathies in iRBD patients. In this context, electroencephalographic (EEG) slowing occurring while awake and asleep, which is frequently observed in DLB, has received much attention. Clarification of the association between EEG slowing and the presence of mild cognitive impairment, which is also commonly seen in early stages of DLB, has been particularly expected to offer a breakthrough for the identification of cases which might convert to α-synucleinopathies. In this article, we introduce the progress in quantitative EEG research in iRBD during the past decade. We also discuss the relationship between EEG findings and cognitive decline as well as the mechanisms of EEG changes or cognitive abnormalities in patients with the disorder.

show abstract

Section: Disease Concept Prevalence and Clinical Correlates Of The Rmentioning

confidence: 99%

Electroencephalographic Finding in Idiopathic REM Sleep Behavior Disorder

2015

View full text Add to dashboard Cite

show abstract

“…Nous suivons présentement une grande cohorte de patients atteints de TCSP. Nous avons au cours des dernières années identifié dans cette cohorte la présence de marqueurs précoces d'apparition d'une maladie neurodégénérative par l'étude du fonctionnement cognitif et moteur, la perception olfactive, l'identification des couleurs, l'analyse quantifiée de l'EEG, l'étude du système nerveux autonome et la mesure du débit sanguin cérébral régional (Gagnon, et al, 2006 ;Massicotte-Marquez et al, 2005 ;Postuma, Gagnon, Vendette, & Montplaisir, 2009 ;Vendette et al, 2011). Enfin, l'étude longitudinale de cette cohorte a montré que près de 80 % des patients TCSP dévelop-paient, dans un délai de 8 ans, une maladie dégénérative de type synucléinopathie, surtout la maladie de Parkinson ou la démence à corps de Lewy (Postuma, Gagnon, Bertrand, Genier Marchand, & Montplaisir, 2015).…”

Section: -Les Parasomnies De Sommeil Paradoxalunclassified

La médecine du sommeil : 1965-2015

Montplaisir

2015

smq

Self Cite

View full text Add to dashboard Cite

La médecine du sommeil a maintenant 50 ans. À l’Université de Montréal, le Centre d’étude du sommeil naissait il y a environ 40 ans et a grandi pour devenir en 2012 le Centre d’études avancées en médecine du sommeil (CÉAMS). Le CÉAMS, c’est 14 chercheurs, plus de trente stagiaires de recherche et un personnel hautement qualifié. C’est un laboratoire de 1,500 mètres carrés comprenant 10 salles d’enregistrement polygraphique du sommeil, 3 laboratoires d’isolation temporelle pour l’étude des rythmes circadiens, un laboratoire d’enregistrement EEG à haute densité, un système d’imagerie SPECT à haute résolution et une clinique qui agit comme lieu de formation clinique et comme centre de référence pour plusieurs pathologies du sommeil, telles que la narcolepsie, le bruxisme, le syndrome des jambes sans repos et le trouble comportemental en sommeil paradoxal. Cet article raconte l’histoire du CÉAMS, ses principales réalisations et ses projets d’avenir en parallèle avec le développement général de la médecine du sommeil.The Département de psychiatrie de l’Université de Montréal houses one of the first sleep centers founded 40 years ago. This center contributed to virtually every aspect of sleep medicine. It grew considerably over time to become one of the largest sleep centers worldwide. It is now called the Center for Advanced Research in Sleep Medicine (CARSM). Fourteen researchers and more than 30 research PhDs and postdoctoral fellows are working together in a 1,500 square-meter facility that includes separate units for fundamental and clinical studies and for the sleep disorders clinic. It has 10 polysomnographic recording rooms, 3 isolated units devoted to chronobiological studies, a high resolution SPECT imaging laboratory specifically devoted to sleep research, a high-density EEG unit and a psychophysiological laboratory to study the interaction between pain and sleep. This article relates the history of the CARSM and also presents a personal sleep odyssey.The CARSM has been very active in the description of clinical features and definitions of the phenotype of most sleep disorders. It contributed specifically to the development of diagnostic tools in narcolepsy (the multiple sleep latency test in different age groups), in nocturnal epilepsy (development of a method to localize the primary focus using in-depth electrodes recording during rapid eye movement sleep), in sleep bruxism (a method for scoring masticatory muscle activity during sleep and definition of cut-off values), in the restless legs syndrome (RLS: the suggested immobilisation test), in sleepwalking (sleep deprivation and experimental awakenings) and REM sleep behaviour disorder (RBD: development of the first polygraphic method to diagnose RBD).The CARSM also contributed to the knowledge on the epidemiology of sleep disorders, conducting the first population-based prevalence study of RLS and of sleep bruxism. Researchers at the CARMS also looked at the impact of sleep disorders like narcolepsy, RLS, sleep apnea and the parasomnias on daytime cogniti...

show abstract

“…This activity was defined prealpha because it was suppressed by eye opening. Two studies [81,82] quantified EEG characteristics during polisomnography (PSG) in patients with RBD and DLB/PDD and indicated differences with controls in the same EEG frequency band. QEEG was analyzed with different methods.…”

Section: Quantitative Eeg:qeegmentioning

confidence: 99%

Is There a Place for Clinical Neurophysiology Assessments in Synucleinopathies?

Onofrj¹,

Bonanni²,

Thomas³

et al. 2011

Neuroimaging for Clinicians - Combining Research and Practice

View full text Add to dashboard Cite

IntroductionParkinson Disease (PD), Dementia with Lewy Bodies (DLB) and Multiple System Atrophy (MSA) are characterized by deposition of Lewy Bodies (LB), consisting of eosinophilic intracellular (intraneural in PD and DLB and intraglial in MSA) inclusions of -synuclein and allowing the three disorders to be categorized as synucleinopathies. The identification in the last two decades of specific clinical features of synucleinopathies has been a major breakthrough in Neurology, as it prompted a reconsideration of diagnostic and therapeutic approaches to dementia and parkinsonism. The recognition of synuclein and ubiquitin markers in dementia resulted in the reclassification of patients previously considered as affected by Alzheimer Disease (AD) and Vascular Dementia (VaD), and there is now agreement that DLB is the second most common cause of dementia in elderly population: its prevalence is reported to be in the 25-43% range in different studies. DLB is clinically characterized by the presence of prominently dysexecutive dementia (frontal lobe or subcortical dementia according to earlier classification [1]), cognitive fluctuations, consisting of remitting-relapsing episodes of blunted conscience reaching levels of stupor, by the occurrence of visual hallucinations and delusions, by parkinsonian motor signs and hypersensitivity to neuroleptic treatment, ranging from worsening of parkinsonism to the possible lethal neuroleptic-malignant syndromes [2]. Yet, variances of presentation and overlapping symptoms with AD and Fronto-Temporal lobe Degeneration (FTD), could be misleading in the process of addressing a clinical diagnosis with consequent therapeutic risks(e.g. introducing neuroleptic treatments in patient with DLB), or economic costs (e.g. addressing patients with DLB to treatment protocols dedicated to AD patients, based on vaccines or antibodies against amyloid proteins, a neuropathological feature of AD). It is evident the stringent need for improvement of reliable diagnostic tools (u.e. biomarkers) to differentiate the diseases associated with dementia. In 2010 the National Institute of Health, NIH, held a symposium focused on the development of possible biomarkers for DLB. Among the different suggested biomarkers, neurophysiological assessments were reconsidered, as a large amount of neurophysiological studies had been devoted to AD and PD, whose characteristics are shared by DLB. www.intechopen.com Neuroimaging for Clinicians -Combining Research and Practice 300We contributed to several studies on this argument along the years, and in the present chapter we discuss the role of clinical neurophysiological studies in DLB in comparison with other disorders. The essential background of our original studies laid in the fact that most historical studies were performed when the DLB clinical entity was unknown and therefore some of the past results were marred by absent recognition of this clinical entity. Synucleinopathies: Dementia with lewy bodiesSynucleinopathies comprise a diverse groups of neurodegenerati...

show abstract

Slow‐wave sleep and delta power in rapid eye movement sleep behavior disorder

Cited by 75 publications

References 35 publications

Electroencephalographic Finding in Idiopathic REM Sleep Behavior Disorder

Electroencephalographic Finding in Idiopathic REM Sleep Behavior Disorder

La médecine du sommeil : 1965-2015

Is There a Place for Clinical Neurophysiology Assessments in Synucleinopathies?

Contact Info

Product

Resources

About